Company intelligence / Profile preview

Shanghai Renyuan Biotech

Shenzhen, Guangdong Sheng, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Renyuan Biotechnology (Shenzhen) Co., Ltd. has three preclinical programs in stem cell therapy targeting nervous system diseases such as stroke and ischemia. No clinical results have been reported yet.

Therapeutic areas: CardiovascularNeurology
Modalities: Stem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Renyuan Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Renyuan Biotech.

Explore the full profile